SC291 for B-Cell Malignancies
Trial Summary
What is the purpose of this trial?
This trial tests SC291, a new drug for blood cancers, in patients with NHL or CLL who have tried multiple treatments. SC291 is given after chemotherapy to better target cancer cells.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have had systemic anticancer therapy or radiotherapy within 14 days of starting the trial (28 days for biologics).
What data supports the effectiveness of the treatment SC291 for B-Cell Malignancies?
Is SC291 safe for humans?
How does the drug SC291 work differently for B-cell malignancies?
SC291 is unique because it targets the B29 gene, which is often mutated in B-cell malignancies like chronic lymphocytic leukemia (CLL). These mutations affect the B cell receptor's ability to signal properly, and SC291 aims to correct these mutations, potentially improving the effectiveness of existing treatments.1112131415
Research Team
Cori Abikoff, MD
Principal Investigator
Sana Biotechnology, Inc.
Eligibility Criteria
This trial is for adults aged 18-75 with certain B-cell malignancies, including various types of non-Hodgkin's lymphoma and chronic leukemias. Participants must have relapsed or refractory disease after at least two prior treatments or a stem cell transplant, be relatively fit (ECOG status 0 or 1), and have a life expectancy of at least 12 weeks.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepleting Chemotherapy
Participants receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide
Treatment
Participants receive the investigational treatment SC291 following chemotherapy
Follow-up
Participants are monitored for safety, tolerability, and anti-tumor activity
Treatment Details
Interventions
- SC291
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sana Biotechnology
Lead Sponsor